About us

Lawarence press is an information solution company’s endeavour to bring information among research professionals of the health, science and technology sectors.
We publish contents with the mission to provide information which is universally accessible. We provide easily accessible and elegant online publishing solutions.
Our mission is to empower research work providing web-based digital publishing platform solutions of an international standard. .
Our company vision is to provide the highest standard in an online publishing platform.
We value innovation, originality & quality.

A Meta-Analysis of Efficacy and Safety Evaluation Between Desloratadine Citrate Disodium Versus Loratadine Tablets in Patients with Chronic Urticaria

Lina Zhao, Zhuoru Liang, Yang Wang, Jie Jiang, Tiantian Zhang


Objective To summarize the available evidence and assess the efficacy and safety of desloratadine citrate disodium versus loratadine in patients with chronic urticaria (CU).

Methods Databases PubMed (Medline), Web of knowledge, MEDLINE, VIP, Wanfang and CNKI databases were systematically searched for articles. The search results were last updated in June 2017. Quality assessment and data extraction were performed according to the Cochrane Handbook. The meta-analysis was performed using Stata 14.0.

Results Nine randomized controlled trials involving 950 patients were identified. In terms of efficacy, the pooled ORs for the overall responder rate and the complete remission rate were 2.37 (95% CI: 1.77–3.16) and 2.86 (95% CI: 2.25–3.64), respectively. The pooled ORs for 7 days overall responder rate, 14 days overall responder rate, 28 days overall responder rate were 1.92 (95% CI: 1.32–2.79), 3.71 (95% CI: 1.98–6.95),2.64 (95% CI: 1.32–5.27) respectively. The pooled ORs for 7 days complete remission rate, 14 days complete remission rate, 28 days complete remission rate were 2.29 (95% CI: 1.38–3.79), 3.46 (95% CI: 2.28–5.23), 2.78 (95% CI: 1.93–4.01) respectively. In the terms of safety, the pooled OR for adverse events (AEs) was 0.42 (95% CI: 0.24–0.71), with statistical significance. The most common AEs were somnolence, thirst, dizziness, weakness and nausea.

Conclusion Desloratadine citrate disodium is more efficacious and safer than loratadine in patients with CU.


chronic urticaria, loratadine, desloratadine citrate disodium, meta-analysis

Full Text:


Greaves MW. Chronic urticaria. N Engl J Med. 1995;332:1767–1772.

Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol. 2010;35:869–873.

Guo Z. Assessment and influences of the life quality of patients with chronic urticaria. Medical Recapitulate. 2016;22:790–791 and 794.

Jin R, Jin L. Advances in chronic urticaria study. Chinese J Gen Prac. 2009;7:997–999.

Li M, Zhang X. The pharmacological effects and clinical application of loratadine. Chin J Mod Drug Appl. 2013;7:159–160.

Liu W, He G, Cui J. A Review of the research on desloratadine citrate disodium, a new antihistamine drug. Guangdong Chemical Industry. 2014;20:159–160.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65–W94.

Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8:2–10.

Wang Z, Yang X. Efficacy and safety of desloratadine citrate disodium tablets for chronic urticaria. Chongqing Medicine.2013;42:1401–1403.

Chen H. Clinical observation of desloratadine citrate in the treatment of chronic urticaria. Guide of China Medicine.2015;13:199–200.

Liang Z. Clinical analysis of desloratadine citrate disodium for chronic urticaria. Medical Information. 2015;28:21.

Hu Y. Efficacy and adverse events analysis of desloratadine citrate disodium for chronic idiopathic urticaria. Medical science. 2016;11:00192.

Yang H, Ma H. Clinical research of desloratadine citrate disodium tablets for chronic urticaria. Medicine. 2017;2:00012–3.

Ren J. Efficacy and safety of desloratadine citrate disodium for chronic urticaria. China Health Care Nutrition. 2016:257.

Chen G. Efficacy and safety of desloratadine citrate disodium for chronic urticaria. Front Med. 2016;6:111–112.

Hua Y. Efficacy and safety of desloratadine citrate disodium for chronic idiopathic urticaria. Medical Science. 2016:00114.

Deng B, Yang L, Gong D. Efficacy and safety of desloratadine citrate disodium tablets for chronic urticaria. Evaluation and analysis of drug-use in hospitals of China. 2017;17:518–520.

Sharma M, Bennett C, Carter B, Cohen SN. H1-antihistamines for chronic spontaneous urticaria: an abridged cochrane systematic review. J Am Acad Dermatol. 2015;73:710–716.e4.

Ferrer M, Sastre J, Jauregui I, Davila I, Montoro J, del Cuvillo A, et al. Effect of antihistamine up-dosing in chronic urticaria. J Invest Allerg Clin Immunol. 2011;21:34–39.

Meador KJ, Yang H, Piña-Garza JE, Laurenza A, Kumar D, Wesnes KA. Cognitive effects of adjunctive perampanel for partial-onset seizures: A randomized trial. Epilepsia. 2016;57:243–251.


  • There are currently no refbacks.

Copyright (c) 2017 Journal of Pharmaceutical and Biomedical Sciences

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.